GGrantIndex
← Leaderboards

Shifa Biomedical Corporation

Malvern, PA

Compare ↔
$12,341,787
Total funding
16
Grants

Funding over time

peak $1.4M · FY2006–25
$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$12,341,787 · 16

By mechanism

R44$9,532,552 · 6
R43$2,809,235 · 10

Investigators at Shifa Biomedical Corporation

Investigator-initiatedAll funding

InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).

Rising Stars

First grant in the last 5 yrs

Not enough data

Emerging Leaders

6–10 yrs in

1Harold Vernon Meyers$143,4731 gr

All-Time

Most funded here, all years

1Nabil A Elshourbagy$7,123,3497 gr2Sherin S Abdel-Meguid$2,093,7394 gr3Michael N Blackburn$643,9492 gr4Arnold T Hagler$574,7102 gr5Harold Vernon Meyers$143,4731 gr

Largest grants

Executing the IND-Enabling Studies for Oral PCSK9/LDLR antagonist$1,267,886
R44 · FY2024 · HL
Executing the IND-Enabling Studies for Oral PCSK9/LDLR antagonist$1,150,186
R44 · FY2025 · HL
Oral PCSK9/LDLR antagonist direction to the clinic$945,393
R44 · FY2021 · HL
Oral PCSK9/LDLR antagonist direction to the clinic$943,895
R44 · FY2020 · HL
Novel Modulators of HDL Metabolism$785,643
R44 · FY2012 · HL
Novel Modulators of HDL Metabolism$753,972
R44 · FY2013 · HL
Development of Oral Small Molecule PCSK9 Antagonist$682,343
R44 · FY2017 · HL
Structure-Based Search for Novel Antihypercholestrolemic Agent$681,349
R44 · FY2010 · HL
Development of Oral Small Molecule PCSK9 Antagonist$666,558
R44 · FY2018 · HL
Structure-Based Search for Novel Antihypercholestrolemic Agent$655,327
R44 · FY2011 · HL
Novel Modulators of LDL Metabolism$500,000
R44 · FY2015 · HL
Novel Modulators of LDL Metabolism$500,000
R44 · FY2014 · HL
Novel Self-Limiting Prothrombinase Inhibitors$347,218
R43 · FY2012 · HL
A Novel Cassette System for the Assembly of VLP Vaccines$296,731
R43 · FY2012 · AI
Structure-Based Design of Novel HNF4a Antagonists to Treat Metabolic Syndrome$290,230
R43 · FY2010 · DK
Improving Solubility, Stability and Permeability of Natural Products Extracts$286,946
R43 · FY2019 · AT
Dynamic, Structure Driven Fragment Based Design of Selective Androgen Modulators$284,480
R43 · FY2008 · CA
Novel Modulators of HDL Metabolism$270,518
R43 · FY2009 · HL
Structure-Based Search for Novel Antihypercholestrolemic Agents$258,966
R43 · FY2008 · HL
Novel Modulators of LDL Metabolism$258,591
R43 · FY2009 · HL